(Reuters) – Pfizer Inc and BioNTech said on Wednesday they have initiated submission for a full approval of a booster dose of their COVID-19 vaccine in people aged 16 years and older, potentially paving the way for a third dose that can be offered to people with compromised immune systems.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
